Novel aspects of postprandial lipemia in relation to atherosclerosis.
Postprandial hyperlipidemia is considered to be a substantial risk factor for atherosclerosis. Interestingly, this concept has never been supported by randomized clinical trials. The difficulty lies in the fact that most interventions aimed to reduce postprandial lipemia, will also affect LDL-C levels. The atherogenic mechanisms of postprandial lipids and lipoproteins can be divided into direct lipoprotein-mediated and indirect effects; the latter, in part, by inducing an inflammatory state. Elevations in postprandial triglycerides (TG) have been related to the increased expression of postprandial leukocyte activation markers, up-regulation of pro-inflammatory genes in endothelial cells and involvement of the complement system. This set of events is part of the postprandial inflammatory response, which is one of the recently identified potential pro-atherogenic mechanisms of postprandial lipemia. Especially, complement component 3 levels show a close correlation with postprandial lipemia and are also important determinants of the metabolic syndrome. In clinical practice, fasting TG are frequently used as reflections of postprandial lipemia due to the close correlation between the two. The use of serial capillary measurements in an out-of-hospital situation is an alternative for oral fat loading tests. Daylong TG profiles reflect postprandial lipemia and are increased in conditions like the metabolic syndrome, type 2 diabetes and atherosclerosis. Studies are needed to elucidate the role of postprandial inflammation in atherogenesis and to find new methods in order to reduce selectively the postprandial inflammatory response. Future studies are needed to find new methods in order to reduce selectively the postprandial inflammatory response.
Alipour
A
A
Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, The Netherlands.
Elte
J W F
JW
van Zaanen
H C T
HC
Rietveld
A P
AP
Castro Cabezas
M
M
D050197:Atherosclerosis / Q000209:etiology* / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000378:metabolism*; D007962:Leukocytes / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism*; D019518:Postprandial Period / Q000502:physiology*
D008074:Lipoproteins